mercredi 26 février 2020

Onco Actu du 26 février 2020


3.1 PRÉVENTION - TABAC



Opinion: ‘Widening health inequalities in England should be a wake-up call for the Government’ [Cancer Research UK]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



'Electronic nose' could smell breath to warn about higher risk of oesophageal cancer [The Guardian]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Mapping genetic variants driving toxicity to leukemia therapy [St. Jude Children's Research Hospital]











4.9 DÉP., DIAG. & PRONO. - SEIN



Abbreviated MRI outperforms 3-D mammograms at finding cancer in dense breasts [ECOG-ACRIN]










Mammography in Women Older Than 75 Does Not Confer an Additional Survival Benefit [AJMC]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Mouse Study Points to Strategy for Preserving Bone During Chemotherapy [NCI]











5.10 TRAITEMENTS - ESSAIS



Federal judge rules clinical trial sponsors must publish a decade’s worth of missing data [STAT]











5.12 IMMUNOTHÉRAPIES



Largest Real World Dataset of Immune Checkpoint Inhibitors in Melanoma Treatment Demonstrates Similar Outcomes to Randomised Clinical Trials [ESMO]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Genentech pays Bicycle $30M upfront to form discovery-stage immuno-oncology pact [Fierce Biotech]











Bicycle Therapeutics Lands $30M From Genentech in New Cancer R&D Pact [Xconomy]











Bicycle Therapeutics takes Roche's Genentech on an up to $2B immuno-oncology ride [EndPoints]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



IMV's T-cell programming treatment keeps ovarian cancer at bay in midphase study [Fierce Biotech]











IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer [IO Biotech]











5.2.3 PHARMA - ÉCONOMIE



As shortages draw spotlight, Sanofi to spin out drug ingredient business [Biopharma Dive]











5.4 TRAITEMENTS - ECONOMIE



When drug value assessment meets real-world evidence: ICER enlists Aetion in pricing evaluation [EndPoints]











6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES



Unlock ways to share data on peer review [Nature]











Invest 5% of research funds in ensuring data are reusable [Nature]










6.7.1 IA/BIOINFORMATIQUE



What AI still can’t do [MIT Technology Review]